EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Metronomic S-1 Adjuvant Chemotherapy Improves Survival in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma

Yi-Feng Yu, Peng Wu, Rui Zhuo, San-Gang Wu

Cancer Research and Treatment · 2024

DOI: 10.4143/crt.2023.1343 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Research and Treatment, 2024. Verfasst von Yi-Feng Yu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, the First Affiliated Hospital of Xiamen Universi…. Hauptthemen laut MEDLINE: Tegafur, Oxonic Acid, Nasopharyngeal Carcinoma, Drug Combinations. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study aimed to investigate the efficacy and safety of using metronomic S-1 adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma (LANPC).Materials and Methods We retrospectively collected data on patients diagnosed with LANPC between January 2016 and December 2021. All patients were treated with induction chemotherapy and concurrent chemoradiotherapy with or without metronomic chemotherapy (MC). Toxicities during MC were recorded. The chi-square test, Kaplan-Meier methods, propensity score matching (PSM), and Cox proportional hazards model were used for statistical analyses.

Results

A total of 474 patients were identified, including 64 (13.5%) and 410 (83.5%) patients with or without receiving MC, respectively. Patients who received metronomic S-1 had significantly better 3-year locoregional recurrence-free survival (LRFS) (100% vs. 90.9%, p=0.038), distant metastasis-free survival (DMFS) (98.5% vs. 84.1%, p=0.002), disease-free survival (DFS) (98.4% vs. 77.5%, p < 0.001), and overall survival (OS) (98.0% vs. 87.7%, p=0.008) compared to those without metronomic S-1. The multivariate prognostic analysis revealed that metronomic S-1 was identified as an independent prognostic factor associated with better DMFS (hazard ratio [HR], 0.074; p=0.010), DFS (HR, 0.103; p=0.002) and OS (HR, 0.127; p=0.042), but not in LRFS (p=0.071). Similar results were found using PSM. Common adverse events observed in the metronomic S-1 group included leukopenia, neutropenia, increased total bilirubin, anorexia, rash/desquamation, and hyperpigmentation. All patients with adverse events were grade 1-2.

Conclusion

It is worth conducting a randomized controlled trial to assess the effect of metronomic S-1 on survival outcomes and toxicities of LANPC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TegafurOxonic AcidNasopharyngeal CarcinomaDrug CombinationsAdministration, MetronomicNasopharyngeal NeoplasmsHumansFemaleMaleMiddle AgedRetrospective StudiesChemotherapy, AdjuvantAdultAgedChemoradiotherapyAntimetabolites, AntineoplasticTreatment OutcomePrognosisYoung Adult

Stichwörter der Autor:innen

EfficacyMetronomic chemotherapyNasopharyngeal carcinomaS-1Safety

Substanzen

TegafurOxonic AcidS 1 (combination)Drug CombinationsAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • Department of Radiation Oncology, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, the First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
  • School of Medicine, Sun Yat-sen University, Shenzhen, China.

Zitieren

APA

Yu, Y. F., Wu, P., Zhuo, R., & Wu, S. G. (2024). Metronomic S-1 Adjuvant Chemotherapy Improves Survival in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma. Cancer Research and Treatment. https://doi.org/10.4143/crt.2023.1343

Vancouver

Yu YF, Wu P, Zhuo R, Wu SG. Metronomic S-1 Adjuvant Chemotherapy Improves Survival in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma. Cancer Research and Treatment. 2024. doi:10.4143/crt.2023.1343

BibTeX
@article{Yu2024,
  author = {Yu, Yi-Feng and Wu, Peng and Zhuo, Rui and Wu, San-Gang},
  title = {Metronomic S-1 Adjuvant Chemotherapy Improves Survival in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma},
  journal = {Cancer Research and Treatment},
  year = {2024},
  doi = {10.4143/crt.2023.1343}
}
Kostenlos starten →